Search

Your search keyword '"Buonomo, A. R."' showing total 67 results

Search Constraints

Start Over You searched for: Author "Buonomo, A. R." Remove constraint Author: "Buonomo, A. R."
67 results on '"Buonomo, A. R."'

Search Results

2. Reusing Data and Metadata to Create New Metadata Through Machine-Learning & Other Programmatic Methods

3. Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience

4. Invasive Fungal Infections in Hospitalized Patients with COVID-19: A Non-Intensive Care Single-Centre Experience during the First Pandemic Waves

5. Clinical features of patients with home isolation SARS-COV-2 infection: A multicenter retrospective study in southern Italy

6. Pneumocystis jirovecii pneumonia in an immunocompetent patient recovered from COVID-19

7. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

8. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

9. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

10. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

11. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

13. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

14. L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV

15. Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy.

16. Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection

17. Exposure to varicella zoster virus is higher in children with autism spectrum disorder than in healthy controls. results from a case-control study

20. Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy

25. Prevalence of herpes simplex virus 1 and 2 antibodies in patients with autism spectrum disorders

26. Hepatitis C screening in the emergency department of a large hospital in Southern Italy: Results of a pilot study

29. Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review

30. mTOR Inhibitor Use Is Associated With a Favorable Outcome of COVID-19 in Patients of Kidney Transplant: Results of a Retrospective Study

31. Trends in Caesarean Section Rate According to Robson Group Classification among Pregnant Women with SARS-CoV-2 Infection: A Single-Center Large Cohort Study in Italy

32. Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies

33. Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma

34. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

35. Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life ‘LIver Network Activity’ (LINA) cohort update results

36. Diabetes and COVID-19: The potential role of mTOR

37. A standardized polyphenol mixture extracted from poplar-type propolis for remission of symptoms of uncomplicated upper respiratory tract infection (URTI): A monocentric, randomized, double-blind, placebo-controlled clinical trial

38. Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials

39. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C

40. Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience

41. Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort)

42. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications

43. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis

44. Successful treatment of KPC-MDR septic shock with ceftazidime-avibactam in a pediatric critically ill patient

45. Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study

46. Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection

47. Incidence and predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CD20 and CD52 surface antigens

48. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis

49. Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn's disease

50. An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy

Catalog

Books, media, physical & digital resources